Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates
Dr. London is a global leader in veterinary targeted therapies. She discusses potential risks to veterinary staff, the value of targeted therapy in times of constrained PPE resources, and the effects of COVID-19 on research activity.
When your dog has cancer and you're also a world-renowned cancer researcher, your interactions with veterinary oncologists are a little different.
Another exciting addition to the FidoCure® oncology toolbox: Olaparib as a new targeted therapy.
Safety and Toxicity of Small Molecule Inhibitors in Dogs with Spontaneously Occurring Malignancies — The Use of Real World Data
The VCS Virtual Conference was held from October 15 - 17, 2020. We had the honor of presenting our abstract during the event.
Dr. Ehrhart shares insight from her current work in comparative aging research and highlights its intersection with cancer and musculoskeletal research in veterinary medicine.Webinars
Why is the Palladia dose used at the clinic often different from the one on the FDA-approved label? Over 100 human targeted therapies have been approved, yet many doses were found to be incorrect in the post market stage. Why is that?Data
Dr. Mason shares insight from the groundbreaking work her team is doing with hemangiosarcoma genetics and discussses the findings from her research on immunology and its influence on the future of veterinary medicine.Webinars